The group benefited in particular from the growth of its Annual Recurring Revenue (ARR), which reached EUR 108.0 million at the end of December 2025, an 8.8% year-on-year increase, illustrating the successful scaling of its business model.

Profitability remains on a favorable trend. Current EBITDA came in at EUR 66.7 million, up 9.1%, reflecting disciplined cost management amid sustained development. Current operating income stood at EUR 48.2 million (+6.8%), factoring in the impact of investments made in the new healthcare data infrastructure.

Net income rose by 8.8% to EUR 41.1 million. On this basis, Equasens will propose a gross dividend of 1.40 euros per share for the 2025 fiscal year, subject to approval at the Annual General Meeting on June 25, 2026.

Concurrently, the group is pursuing its growth strategy through a combination of external acquisitions and technological investments. This trajectory is supported by a strengthening financial position, with a net cash surplus of EUR 83.6 million at the end of 2025, up EUR 4.1 million over the year.

Equasens now intends to consolidate its leadership position in the French and European markets for digital healthcare solutions. Technological innovation will remain at the heart of its strategy, particularly regarding system interoperability, stakeholder coordination, and improving the efficiency of care pathways.

In this context, the deployment of artificial intelligence, a long-standing initiative within the group, is expected to play a key role. In 2026, Equasens plans to continue integrating AI into its business software and to enhance its SaaS offerings hosted on its private healthcare cloud.

The group specifically aims to master a so-called "agentic" AI layer, designed to automate certain tasks, analyze large volumes of data in real time, and assist healthcare professionals in their decision-making process, thereby creating further value for its clients.

Equasens will publish its first-quarter 2026 revenue on April 29.